Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer’s Disease (AD)

 Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer’s Disease (AD)

Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer’s Disease (AD)

Shots:

  • The P-III CREAD-1 and 2 study involves assessing of Crenezumab vs PBO in 1500 patients with early AD with confirmed evidence of cerebral beta-amyloid pathology (CSF or amyloid PET) for a duration of two years
  • The discontinuation process of trial is based on its unmet 1EPs results from baseline Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score with no new safety signals observed
  • Crenezumab is a mAb promotes removal of neurotoxic oligomers targeted for Alzheimer disease in Alzheimer’s Prevention Initiative (API) trial. Additionally, Roche is assessing Gantenerumab, an IgG1 mAb indicated for lowering amyloid plaque in AD patients

Click Here to read full press release/ article | Ref: Roche | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post